A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors.
Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute), Li Yan(Research Triangle Park Foundation), Alastair Greystoke(Newcastle University), Jean‐Charles Soria(Inserm), Anas Gazzah(Institut Gustave Roussy), Kevin Laubscher(Research Triangle Park Foundation), Maria L Mattern(GlaxoSmithKline (United States)), Ruth Plummer(National Health Service), Debra Rogan(Research Triangle Park Foundation), Jolly Mazumdar(Howard Hughes Medical Institute), Sarah P. Blagden(Churchill Hospital), Noelia Nebot(Research Triangle Park Foundation), Lisa S Swartz(Research Triangle Park Foundation), Kurt R. Auger(Research Triangle Park Foundation), Ronald A. Fleming(Research Triangle Park Foundation), Rajendra Singh(GlaxoSmithKline (United States)), Gabriel Mak(Sarah Cannon Research Institute), Ivana Rizzuto(Imperial College Healthcare NHS Trust)
Cited by 7
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Rociletinib in <i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2015|664